Last reviewed · How we verify
NCT00945451
Stereotactic Radiosurgery in Treating Patients Undergoing Chemotherapy and Radiation Therapy For Stage III Non-Small Cell Lung Cancer
NA trial testing CK in Lung Cancer in 35 participants. Completed in 17 November 2016.
17 November 2016
Quick facts
| Lead sponsor | Centre Antoine Lacassagne |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 35 |
| Start date | 24 April 2009 |
| Primary completion | 17 November 2016 |
| Estimated completion | 17 November 2016 |
| Sites | 1 location across France |
Drugs / interventions tested
- CK
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Centre Antoine Lacassagne — full company profile →
Who can join
Adults 18 to 120, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. Giving stereotactic radiosurgery after docetaxel and cisplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and the best dose of stereotactic radiosurgery when given after docetaxel, cisplatin, and radiation therapy and to see how well it works in treating patients with stage III non-small cell lung cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancer.
Stinchcombe TE, Bogart JA. · · 2012 · cited 24× · PMID 22531360 · DOI 10.1634/theoncologist.2012-0020
Verify or expand the search:
- PubMed search for NCT00945451
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Centre Antoine Lacassagne trials
Trials by the same sponsor.
- NCT07429487 — Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Reducing Fati · NA · not yet recruiting
- NCT06782451 — Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity · NA · recruiting
- NCT06606366 — Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplina · NA · recruiting
- NCT06400849 — Comparison of the Efficacy of Cryotherapy Combined With Compression in Preventing Neuropathy · NA · recruiting
- NCT06029218 — Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00945451 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Centre Antoine Lacassagne
- Last refreshed: 16 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00945451.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing